New shuttle session with our in vivo syngeneic tumor models – for cost-saving efficacy studies
07 / 16 / 2019
-
06 / 29 / 2019
Explicyte was pleased to participate to the AACR Virtual Annual Meeting, last week to get breakthroughs in Immuno-Oncology and to present our posters featuring our capacities / platforms that support drug discovery.
06 / 27 / 2019
Relying on our validated in vitro immune cell activation assay based on the HTRF quantitation of key cytokine release, we recently documented functional characterization of PD1 blockade.
05 / 24 / 2019
Syngeneic tumor models were becoming invaluable for preclinical development and evaluation of immuno-based therapies in the presence of a functional immunocompetent system. Explicyte is providing a series of syngeneic mouse models including subcutaneous and orthotopic models, which were fully characterized in terms of their responsiveness to immune checkpoint inhibitors (ICI) and their immune infiltration features using a high throughput-compatible flow cytometry platform.
05 / 21 / 2019
By setting new facilities within the cancer center “Institut Bergonié”, Explicyte - in addition to its preclinical research capabilities - strengthens its development towards clinical translational research, to provide new services based on multiparametric experimental biomarker analysis, for target identification and monitoring of the immune response in the context of clinical trials.
04 / 23 / 2019
Our syngeneic glioma mouse model, based on the intracranial inoculation of Luc2-expressing GL261 cells and bioluminescence imaging for tumor growth monitoring, represents a suitable tool for chemo- and immunotherapy assessment. It closely mimics the human disease in terms of tumor progression and anti-tumor response, and recapitulates glioblastoma characteristic features including among others tumor immune cell infiltration and tumor-induced immunosuppression.
04 / 09 / 2019
We are proud to offer a first in vitro shuttle session on our newly validated M2 macrophage suppression assay, which will take place early June, 2019 – thereby providing an opportunity to timely and cost-effectively assess novel immunotherapeutics.
03 / 25 / 2019
Bordeaux, FRANCE, March 24, 2019: Explicyte and Institut Bergonié, have entered into a collaboration to conjointly drive a translational research program aiming at identifying resistance mechanisms to immune checkpoint inhibitors in cancer patients.
03 / 20 / 2019
We will be attending the AACR Annual Meeting in Atlanta, from March 29 to April 3, 2019. We will be glad to take this opportunity to meet you there, describe our service offerings and approach your research projects.
03 / 13 / 2019
Our newly validated M2 suppression assay based on i) the co-culture of autologous monocyte-derived M2 macrophages and activated CD4+ T cells (or PBMCs) and on ii) the quantitation of IFNg levels as surrogate of T cell activation, is specifically designed to assess new immunotherapeutics for their modulatory activity on the phenotype and function of M2 macrophages.
Candidate compounds can thus be evaluated as single agents or in combinatorial treatments, for their potential to repolarize / switch M2 macrophages and to antagonize M2-mediated T cell suppression.